In present era, drugs like steroids, cytotoxic drugs and calcineurin inhibitors are the backbone to treat immune mediated glomerular diseases. Failure of these therapies often results in persistence of proteinuria, refractory illness and later chronic kidney diseases. The quests to find an answer to such diseases have resulted in the introduction of monoclonal antibodies or target specific drugs. Rituximab is the first monoclonal antibody, which was studied extensively in pauci-immune glomerulonephritis and is now approved for its role in refractory and new onset renal vasculitis. Belimumab has shown role in active systemic lupus erythematous (SLE). With increasing insight in glomerular pathophysiology, many new monoclonal antibodies are now being under trial. Their encouraging results allowed further research on target cytokines, inflammatory mediators and different lymphocyte populations. This review shall discuss monoclonal and their emerging role in glomerulonephritis.
Sonia Sharma, Sanjiv Saxena
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : July 15, 2019